[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359799-105":59,"doc-detail-359799-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","relationships-of-sglt2-inhibition-circulating-metabolites-and-cancer-a-mendelian-randomization-study","Relationships of SGLT2 inhibition, circulating metabolites, and cancer - A Mendelian randomization study","","The effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on cancer remains controversial, prompting a Mendelian randomization analysis to test causality. Two-sample, two-step MR used genetic instruments for SGLT2 inhibition to evaluate both direct cancer effects and mediation by circulating metabolites. Results link SGLT2 inhibition with higher risks for lung, colorectal, skin cancers, and basal cell carcinoma, and a lower risk for brain cancer. Mediation was quantified for specific metabolite pathways and supported broader causal effects via multiple metabolites.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/relationships-of-sglt2-inhibition-circulating-metabolites-and-cancer-a-mendelian-randomization-study/359799/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/relationships-of-sglt2-inhibition-circulating-metabolites-and-cancer-a-mendelian-randomization-study/359799.png","ImageObject",300,407,{"name":92,"@type":93},"Angel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What causal relationship does the study test regarding SGLT2 inhibition and cancer?","Question",{"text":113,"@type":114},"It evaluates whether genetically predicted SGLT2 inhibition causally affects cancer risk and whether circulating metabolites mediate that relationship.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which cancers showed increased or decreased risk with SGLT2 inhibition?",{"text":118,"@type":114},"SGLT2 inhibition was associated with increased risk of lung cancer, colorectal cancer, skin cancer, and basal cell carcinoma, and with decreased risk of brain cancer.",{"name":120,"@type":111,"acceptedAnswer":121},"How were circulating metabolites assessed as mediators in the analysis?",{"text":122,"@type":114},"A two-step, two-sample Mendelian randomization framework estimated mediating proportions through specific metabolites, including pathways involving polyunsaturated fatty acids/omega-6 fatty acids, acetone, and various triglycerides.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},359799,1790237982,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687207412472,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","®  \n Observational Study   \nRelationships of SGLT2 inhibition, circulating metabolites, and cancer  \nA Mendelian randomization study  \nWenhui Li, MDa , Hui Zhou, MDb , Xiaolei Wang, PhDb , Wangyang Li, MSa , Wenying Xie, MDa , Jing Zhang, MSa , Linjing Qiu, MDa , Changjiang Wu, MDa , Taojing Zhang, MDb ,*  \n\n| Abstract\u003Cbr>The effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on cancer remains controversial. This study aimed to investigate the causal relationship between SGLT2 inhibition, circulating metabolites and cancer through Mendelian randomization. Genetic instruments for SGLT2 inhibition were identified as genetic variants. A two-sample, two-step Mendelian randomization approach was adopted to determine the causal relationship between SGLT2 inhibition and cancer, as well as the mediating role of circulating metabolites that link SGLT2 inhibition to cancer. SGLT2 inhibition was associated with an increased risk of lung cancer, colorectal cancer, skin cancer, and basal cell carcinoma, and a decreased risk of brain cancer. The mediation proportions of SGLT2 inhibition through polyunsaturated fatty acids and omega-6 fatty acids concerning colorectal cancer were 2.388% and 2.131% of the total effect, respectively. The mediation proportion of SGLT2 inhibition through acetone concerning skin cancer was 5. 127% . For brain cancer, the mediation proportions of SGLT2 inhibition through medium-high-density lipoprotein triglycerides, high-density lipoprotein triglycerides, and very-low-density lipoprotein triglycerides were 2.648%, 2. 131%, and 2.095%, respectively. Our study established the causal effects of SGLT2 inhibition on circulating metabolites. SGLT2 inhibition can influence cancer through various metabolites.\u003Cbr>Abbreviations: CI = confidence interval, GWAS = genome-wide association study, HbA1c = glycated hemoglobin, HDL = highdensity lipoprotein, IVW = inverse-variance weighted, M-HDL = medium-high-density lipoprotein, MR = Mendelian randomization, NSCLC = non-small cell lung cancer, OR = odds ratio, PUFAs = polyunsaturated fatty acids, SGLT2 = sodium-glucose cotransporter 2, SNPs = single-nucleotide polymorphisms, T2DM = type 2 diabetes mellitus, TGs = triglycerides, VLDL-TG = very-low-density lipoprotein triglycerides. |\n| --- |\n| Keywords: cancer, circulating metabolites, Mendelian randomization, SGLT2 inhibition |\n\n1. Introduction  \nCancer represents a substantial public health challenge, with global statistics indicating that nearly 20 million new cases were diagnosed and 9.7 million deaths attributed to cancer in 2022.[1] Lung cancer is the leading cause of both incidence and mortality, followed closely by female breast cancer, colorectal cancer, prostate cancer, and gastric cancer, all of which show high diagnosis rates. The sodium-glucose cotransporter 2 (SGLT2) is expressed in various cancer cell types, including those found in pancreatic cancer, prostate cancer, and glioblastoma. [2] A study has confirmed that glioma cells utilize SGLT2 for glucose uptake, a process that can be inhibited by the SGLT2 inhibitor canagliflozin. [3]  \nSGLT2 inhibitors constitute a novel class of antidiabetic medications that promote urinary glucose excretion and lower serum glucose levels by inhibiting glucose reabsorption in the proximal renal tubules. [4] Beyond glycemic effects, the role in cardio-renal protection has been well-established, and the potential antitumor effects are increasingly gaining attention. Several studies suggest that SGLT2 inhibitors may reduce the risk of specific cancers, such as cervical, prostate and endometrial cancer;[5–7] however, other studies have indicated a potential association with an increased risk of certain cancers.[8] Current evidence primarily stems from observational studies, which are susceptible to confounding factors (e.g. diabetes duration, glycemic control, and concomitant medications) and reverse causality, making it difficult to establish a causal relationship.  \nThis w","cbCaikeo0HKdb39r","https://ap.wps.com/l/cbCaikeo0HKdb39r","pdf",1265975,11,"English","# Introduction\n## Background on SGLT2 inhibitors and cancer\n## Rationale for causal inference\n# Mendelian randomization overview\n## Instrumental variables and bias reduction\n## Role of metabolomics","[{\"question\":\"What causal relationship does the study test regarding SGLT2 inhibition and cancer?\",\"answer\":\"It evaluates whether genetically predicted SGLT2 inhibition causally affects cancer risk and whether circulating metabolites mediate that relationship.\"},{\"question\":\"Which cancers showed increased or decreased risk with SGLT2 inhibition?\",\"answer\":\"SGLT2 inhibition was associated with increased risk of lung cancer, colorectal cancer, skin cancer, and basal cell carcinoma, and with decreased risk of brain cancer.\"},{\"question\":\"How were circulating metabolites assessed as mediators in the analysis?\",\"answer\":\"A two-step, two-sample Mendelian randomization framework estimated mediating proportions through specific metabolites, including pathways involving polyunsaturated fatty acids/omega-6 fatty acids, acetone, and various triglycerides.\"}]","Relationships of SGLT2 inhibition, circulating metabolites, and cancer - A Mendelian randomization study | PDF",1790137854,28,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6fa82fec7599bd3ac6784bdf3f6cbdca.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc6750a24cf321b2ef4b74261238973f.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/370bfed4a6e6a83cb9b2eaf68921c000.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68f98c0420244a2e9da7e1d1a242ae98.webp",980,1306]